Middleton, G., Yang, Y., Campbell, C. D., André, T., Atreya, C. E., Schellens, J. H., . . . Corcoran, R. B. (2020). BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clin Cancer Res.
Citación estilo ChicagoMiddleton, Gary, et al. "BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade With Dabrafenib, Trametinib, and Panitumumab in Patients With Colorectal Cancer." Clin Cancer Res 2020.
Cita MLAMiddleton, Gary, et al. "BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade With Dabrafenib, Trametinib, and Panitumumab in Patients With Colorectal Cancer." Clin Cancer Res 2020.